ライフサイエンスコーパス: p

1 ose for IPF (UCSF 33.3%, p=0.09; UTSW 32.0%, p=0.95).

2 ows: aHR = 1.04 (95% CI 0.54-2.01), I2 = 0%, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and

3 idence of heterogeneity of effect (I(2)=0.0, p=0.56).

4 U discharge (hazard ratio, 0.65 [0.42-1.00]; p = 0.01), longer delirium duration (incidence rate rati

5 nd disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

6 ia scale (PAS) scores (beta=0.005, SE=0.002, p=0.021, n=131) among cases in the MPIP study.

7 ation (risk ratio, 0.50 [95% CI, 0.25-1.01]; p = 0.05; low-quality evidence); no reduction in toleran

8 shock (relative risk = 1.007 [1.002-1.013]; p = 0.006), time-to-first antibiotic (relative risk = 1.

9 d controls (C/TTCTG: gamma(2) value = 0.014; p = 0.904).

10 of 2 mg/L or above (HR(adj)=0.90, 0.79-1.02, p=0.11).

11 tes (-0.09 SD/decade, 95% CI [-0.16, -0.02], p = 0.009).

12 disposition index (beta = 0.056, SE = 0.026; p = 0.035).

13 = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603.

14 %, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603.

15 imit of reactivity, 1.04; 95% CI, 1.02-1.06; p < 0.001) and mortality (odds ratio, 1.06; 95% CI, 1.04

16 0001), combination therapy (1.53, 1.13-2.07; p=0.054), and have their blood pressure controlled (2.06

17 tality (odds ratio, 1.06; 95% CI, 1.04-1.08; p < 0.001).

18 justed ICD HR: 0.921; 95% CI: 0.787 to 1.08; p = 0.31), whereas those with SPRM above the median deri

19 uation II (relative risk = 1.05 [1.02-1.09]; p = 0.003), Sequential Organ Failure Assessment (relativ

20 fraction (45.6 +/- 17.4% vs. 55.3 +/- 11.1%; p < 0.001).

21 ally significant (0.2 [SD 1.1] vs 0.1 [1.1], p=0.010) difference between the two groups in change fro

22 ted odds ratio [OR] 2.23, 95% CI 1.59-3.12); p<0.0001), combination therapy (1.53, 1.13-2.07; p=0.054

23 ans (-0.20 SD/decade, 95% CI [-0.28, -0.12], p < 0.001) than for whites (-0.09 SD/decade, 95% CI [-0.

24 oint estimate=0.078 (95% CIs: 0.003, 0.168), p=0.03).

25 ascular risk factors (HR = 1.07 [0.98-1.17], p = 0.1374, and HR = 1.17 [0.96-1.42], p = 0.1206, respe

26 ssessment (relative risk = 1.09 [1.00-1.18]; p = 0.04), presence of shock (relative risk = 1.007 [1.0

27 nts with normoalbuminuria, -25% (-31 to -19; p<0.0001) in patients with microalbuminuria, and -32% (-

28 ted improvement in LF only (3 +/- 6 ml/m(2); p = 0.02).

29 0-1) at day 90 (OR 7.6, 95% CI 1.6 to 37.2, p=0.010).

30 ith empagliflozin was -7% (95% CI -12 to -2; p=0.013) in patients with normoalbuminuria, -25% (-31 to

31 g treatment (OR: 0.99; 95% CI: 0.82 to 1.20, p=0.909).

32 with microalbuminuria, and -32% (-41 to -23; p<0.0001) in patients with macroalbuminuria.

33 ogical brain tumor diagnosis (beta = -0.253, p < 0.001).

34 not related to a stented site (59% vs. 26%, p = 0.001).

35 at baseline and end of therapy, Z >/= -2.27, p </= .023.

36 relative risk (RR)=1.14 (95% CI: 1.02, 1.27; p=0.024) for a lag of 2 wk; the estimated risk increased

37 d 3 hours (relative risk = 0.09 [0.03-0.27]; p < 0.0001).

38 with more than 5 radon Spearman's Rho 0.286 (p-value < 0.001) and Spearman's Rho 0.509 (p-value < 0.0

39 p (hazard ratio [HR] 1.08, 95% CI 0.91-1.29; p=0.36).

40 s were similar to those for IPF (UCSF 33.3%, p=0.09; UTSW 32.0%, p=0.95).

41 pital mortality was similar (12.4% vs 10.3%; p = 0.635).

42 tiapine-ER (15 [30%] of 50; estimated 31.3%; p=0.0021), but not at other timepoints.

43 3, rho = 0.56, p < 0.05; n = 13, rho = 0.30, p = 0.317).

44 eath (hazard ratio, 1.07; 95% CI, 0.88-1.30; p = 0.52).

45 in the MMN group scored 0.18 SD (0.06-0.31, p=0.0047) higher in general intellectual ability, simila

46 4) and less time hyperglycaemic (27% vs 32%; p=0.0279) than did pregnant control participants, with c

47 I -7.0 to 4.3; hazard ratio 0.96, 0.68-1.35, p=0.81).

48 ine difference 2231 pg/dl, 95% CI: 897-3566, p = 0.0013).

49 ntibiotic (relative risk = 1.22 [1.09-1.36]; p = 0.0006), antibiotic administration within 6 hours (r

50 as significant (beta=0.22, 95% CI 0.05-0.39; p=0.013).

51 , 4 hours (relative risk = 0.16 [0.06-0.39]; p = 0.0001), and 3 hours (relative risk = 0.09 [0.03-0.2

52 rol) and time spent hypoglycaemic (3% vs 4%; p=0.10).

53 VAS-Anxiety (Time x Treatment: F10,141=0.4, p=0.95).

54 1.3-1.9, p<0.0001) or culture (1.7, 1.2-2.4, p=0.01).

55 isits until week 24 was 2.4 (95% CI 0.4-4.4, p=0.0182).

56 p, namely 3-O-caffeoylquinic acid (3-CQA), 4-p-coumaroylquinic acid (HC1), 4-O-caffeoylquinic acid (4

57 two groups (HR: 1.09; 95% CI: 0.84 to 1.42; p = 0.53).

58 .17], p = 0.1374, and HR = 1.17 [0.96-1.42], p = 0.1206, respectively).

59 feeds (risk ratio, 0.94 [95% CI, 0.62-1.42]; p = 0.77; low-quality evidence), and no change in the du

60 n 6 hours (relative risk = 0.20 [0.09-0.45]; p = 0.0001), 4 hours (relative risk = 0.16 [0.06-0.39];

61 t (29.6pg/ml, IQR = 20.9-41.8; beta = 1.461, p = 0.005 and beta = 1.902, p = 0.002, respectively).

62 with increased bone-marrow activity (r=0.47; p<0.0001), arterial inflammation (r=0.49; p<0.0001), and

63 the radial systolic peak strain (r = 0.478, p = 0.045).

64 summation operatorBDE-47, -99, -100 = 0.48, p = 0.09), but not dust PBDE.

65 7; p<0.0001), arterial inflammation (r=0.49; p<0.0001), and risk of cardiovascular disease events (st

66 ion (incidence rate ratio, 2.47 [1.36-4.49]; p = 0.005), and increased risk for delirium the followin

67 blood pressure controlled (2.06, 1.69-2.50; p<0.0001) than were those in communities where blood pre

68 (p-value < 0.001) and Spearman's Rho 0.509 (p-value < 0.001) for males and females, respectively.

69 tphone data (surrogates: n = 13, rho = 0.56, p < 0.05; n = 13, rho = 0.30, p = 0.317).

70 neutral genetic data (on average r = 0.574, p < 0.001).

71 following day (odds ratio, 2.83 [1.27-6.59]; p = 0.02).

72 t differences in 5-year OS (36.7% vs. 44.6%, p = 0.4289) or 5-year LTP (73.3% vs. 67.9%, p = 0.8897)

73 o have commercial insurance (19.6% vs 10.6%; p < 0.001) than those who were seen initially at a local

74 o on the LSAS (Time x Treatment: F9,115=2.6, p=0.01) but not the VAS-Anxiety (Time x Treatment: F10,1

75 homozygous frameshift change [c.606delinsTA; p.(Lys202Asnfs*?)].

76 users spent more time in target (68% vs 61%; p=0.0034) and less time hyperglycaemic (27% vs 32%; p=0.

77 (adjusted HR: 0.599; 95% CI: 0.530 to 0.677; p < 0.0001).

78 150 mL/min (hazards ratio, 1.00 [0.60-1.69]; p = 0.68).

79 nosed cases (48/77 (62.3%) vs 13/41 (31.7%), p < 0.001).

80 ir primary caregiver (odds ratio [OR] = 1.7, p = 0.029, 95% CI [1.06, 2.76], d = 0.29).

81 22% and adjusted OR 4.9, 95% CI 1.2 to 19.7, p=0.021).

82 ng clones in M1 (19 [95%]) and M2 (15 [75%], p=0.13).

83 point (relative risk 1.76, 95% CI 1.12-2.77, p=0.0045).

84 the early diastolic strain rate (r = -0.782, p < 0.001) and moderately correlated with the radial sys

85 st quintile) (OR = 2.68; 95% CI: 1.06, 6.79; p = 0.04 for BC-by-CRP-interaction).

86 hose with CNS complications (75.8% vs 37.8%; p < 0.001) and varied by type of CNS injury; mortality w

87 gitation moderate or higher (19.4% vs. 6.8%; p = 0.003).

88 identified as a risk factor of BPD (OR 1.8, p = 5.3 x 10(-5)), independently of the robust antenatal

89 194 (mean difference 10.0, 95% CI 0.2-19.8, p=0.046) in the monotherapy group.

90 in (Hb) status (-2.6 g/l; 95% CI -4.5, -0.8; p = 0.005).

91 3), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p < 0.001) compared with warfarin.

92 ome Scale as a continuous outcome (R = 0.82; p = 0.001; z score, 3.39).

93 reported QoL (MD = -0.02, 95% CI -1.22-0.82; p = 0.97) for people with dementia, or caregivers' gener

94 95% confidence interval [CI]: 0.50 to 0.84; p = 0.001), although there was still no significant diff

95 zard ratio [HR(adj)]=0.75, 95% CI 0.66-0.85, p<0.0001), whereas no significant benefit was observed a

96 ; hazard ratio [HR] 0.73 [95% CI 0.62-0.87], p=0.0003).

97 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95%

98 ted odds ratio [aOR] 0.46, 95% CI 0.23-0.89; p=0.02).

99 p = 0.4289) or 5-year LTP (73.3% vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

100 oscopy (odds ratio [OR] 1.6, 95% CI 1.3-1.9, p<0.0001) or culture (1.7, 1.2-2.4, p=0.01).

101 ue than for the intermediate hues (Z = -2.9, p = 0.004).

102 : 2.73; 95% confidence interval: 1.2 to 5.9; p = 0.01).

103 difference [MD] = -0.55, 95% CI -2.00-0.90; p = 0.45) and self-reported QoL (MD = -0.02, 95% CI -1.2

104 8; beta = 1.461, p = 0.005 and beta = 1.902, p = 0.002, respectively).

105 health status (MD = 0.13, 95% CI -1.65-1.91; p = 0.89).

106 mpetition (highest SCI quartile [0.87-0.92]; p=0.0081) than in areas with weaker competition.

107 d to soil humus C accumulation (R(2) = 0.94, p < 0.001).

108 hazard ratio [HR] 0.757, 95% CI 0.607-0.943; p=0.0118).

109 creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.03), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p <

110 e mortality (HR: 0.90; 95% CI: 0.84 to 0.96; p = 0.002), but not with HF readmission (HR: 0.93; 95% C

111 nt period than at the baseline, Z >/= -1.97, p </= .04.

112 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04).

113 success (OR 0.95 per extra year, 0.93-0.98; p<0.001) and clinical benefit (OR 0.95 per extra year, 0

114 benefit (OR 0.95 per extra year, 0.92-0.98; p=0.004).

115 ; relative risk [RR] 0.70, 95% CI 0.50-0.98; p=0.036).

116 ardised hazard ratio 1.59, 95% CI 1.27-1.98; p<0.0001), a finding that remained significant after mul

117 using an Ag-coated microfluidic channel on a p-type silicon nanowire (SiNW) array measured by a multi

118 ltiple-wave admixture by fitting ALD using a p-spectrum.

119 ene (SLG), with the electrons pairing with a p-wave or chiral d-wave symmetry, depending on the posit

120 tes a photoreactive, non-natural amino acid, p-benzoyl-l-phenylalanine, into various positions of the

121 virus production was significantly affected (p < 0.05) after treatment with paclitaxel or nocodazole

122 ther with the universal starvation alarmone (p)ppGpp, polyP has an additive effect on nucleoid dynami

123 d third (median, 0 vs 10.5) assessments (all p < 0.001).

124 nal, motor, and cognitive deterioration (all p < 0.001), independent of mutant HTT CAG repeat size.

125 of the stratified variables were found (all p > 0.05).

126 4E, phosphorylated 4E-binding protein 1, and p-S6 ribosomal protein.

127 no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

128 catechin, chlorogenic acid, caffeic acid and p-coumaric acid varied among species and found the maxim

129 not associated with TDP-43 aggregation, and p-T153/Y155 remained soluble under conditions that promo

130 s hmax/h, hmax being the peak amplitude, and p and q being constants.

131 x Se2(1-x) alloys from n-type to bipolar and p-type is realized.

132 expressed regions with >|2| fold change and p </= 0.05.

133 hway proteins, including the kinases CK2 and p-ERK1/2 and the signaling scaffold KSR1.

134 However, ferulic and p-coumaric acids were abundant in the bound fractions.

135 er nitroaromatics such as p-nitrotoluene and p-nitrophenol.

136 CD4 cells than those with NRTI-DRMs on ART (p = 0.042).

137 ppb along with other nitroaromatics such as p-nitrotoluene and p-nitrophenol.

138 nificantly modified the QT-PM10 association (p=2.11x10(-8)).

139 neurodevelopmental delay with brain atrophy (p.Ser94Arg) and extend the clinical outcomes to a more s

140 ome species with prunasin, tyramine and beta-p-arbutin, may be limited in food applications.

141 , with no heterogeneity by site of bleeding (p=0.5956).

142 s were significantly lower than that of BLS (p<0.05), while significant decreases in the setback and

143 d (ie, extracellular [p = 0.001], cell body [p = 0.003], and neuritic/glial-processes [p = 0.004]).

144 in the mild and moderate-severe groups (both p < 0.001); (2) the mean cone-mediated PLR was reduced s

145 Persistence induced by McC is mediated by (p)ppGpp and requires chromosomally encoded toxin-antitox

146 009] and Instituto de Pesquisas de Cananeia [p = 0.03]) and CD8(+) T-cell frequency (p = 0.04) correl

147 confirmed in 4 (2.1%) versus 6 (3.2%) cases (p = 0.79).

148 mine increases were observed in the caudate (p = 0.1) or putamen (p = 0.8) following methylphenidate

149 MSTN-edited fry had more muscle cells (p < 0.001) than controls, and the mean body weight of ge

150 In OVCa cells, p-Akt Thr-308 was significantly inhibited by intracellul

151 estern blot analysis of pathway checkpoints, p-mTOR (p=0.03) and PI3K-alpha (P = 0.04) were downregul

152 f site-specific incorporation of a clickable p-azido-L-phenylalanine to Uox and strain-promoted azide

153 sessment Scale-cognitive subscale (ADAS-Cog; p=0.011) and Mini-Mental State Examination (MMSE; p=0.00

154 d with 23 (6%) of 367 asymptomatic contacts (p<0.0001).

155 (>30%; false discovery rate [FDR] corrected p < 0.0008) and nontrained WM tests after adaptive WMT (

156 WM tests after adaptive WMT (FDR corrected, p </= 0.001), but not after nonadaptive WMT (training by

157 ve WMT (training by training type corrected, p = 0.01 to p = 0.05) 1 month later.

158 those measuring hs-cTnT rather than hs-cTnI (p = 0.027).

159 In all cultivars, p-hydroxybenzoic, p-coumaric and ferulic acids were the

160 h density functional theory (M06-2X/6-311G(d,p)).

161 934 for DCEMRI (p<0.68) and 0.852 for DCECT (p<0.001).

162 84 for DCEMRI+HB phase vs. 0.934 for DCEMRI (p<0.68) and 0.852 for DCECT (p<0.001).

163 ohorts, including a slightly faster decline (p = 0.021) on the MMSE for Asians (-0.20 SD/decade, 95%

164 en lesion volume and neurocognitive decline (p = 0.0022).

165 trols with concentrations further decreased (p < 0.05) in a TLR5(392Stop) SNP rUTI subgroup.

166 For example, glp-1 mutation only delays p death, while eat-2 mutation reduces P death.

167 518+2T>G, resulting in an in-frame deletion: p.DelQ134_R256).

168 subjects and 5.6% in patients with devices (p = 0.25) Neurocognitive function was similar in control

169 verall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

170 group (coefficients significantly different, p = 0.012).

171 V was associated with tumor differentiation (p < 0.001).

172 ity dose trends for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), poss

173 ase (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to competing causes of death ov

174 structural isomers of the type M2(p-dobdc) (p-dobdc(4-) = 2,5-dioxido-1,4-benzenedicarboxylate).

175 (0.149 mean episodes vs 0.146 mean episodes; p=0.522).

176 R models for benzene, toluene, ethylbenzene, p-xylene, m-xylene, o-xylene (BTEX), and total BTEX usin

177 We find that the repulsion exponent p approximately 6.5 provides an excellent fit for the ex

178 all compartments studied (ie, extracellular [p = 0.001], cell body [p = 0.003], and neuritic/glial-pr

179 ed in 18.2% of eyes; 86.4% were myopic eyes (p = 0.01); 81.8% occurred within a 120 days-period follo

180 (-0.140 standard deviations per risk factor, p < 0.0001) and remained significant after adjustment fo

181 hose in refractory ventricular fibrillation (p = 0.017).

182 encoding for desmin intermediate filaments, p.D399Y.

183 tegies that forego transition metal ions for p-block elements have emerged.

184 eia [p = 0.03]) and CD8(+) T-cell frequency (p = 0.04) correlate with T4 to T9 spinal cord cross-sect

185 the most electron donating functional group (p-(CH3CH2)2NPh-MoS2) is the most efficient catalyst for

186 tly higher than those of the non-LABC group (p<0.05).

187 significantly in the moderate-severe group (p = 0.008); (3) no significant differences in the mean r

188 a significant difference between the groups (p<0.001).

189 1) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the group

190 ps (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.7 mm Hg; p = 0.17), whereas the ViR group had more frequent post-

191 for both La3Cu3P4 and La3Cu3As4, under high p-type doping.

192 n extubation readiness test within 10 hours (p < 0.001).

193 NA rhythms were delayed by 0.97 +/- 0.29 hr (p < 0.01), indicating that human molecular clocks may be

194 In all cultivars, p-hydroxybenzoic, p-coumaric and ferulic acids were the most abundant comp

195 Apnea occurred more than hypopnea (p < 0.0001).

196 de-major histocompatibility complex class I (p-MHC I) proteins displayed by antigen-presenting cells.

197 type (WT) mice, LY2828360 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-induced neuropathi

198 cal studies suggest that intra-peritoneal (i.p.) chemotherapy effectively treats residual EOC after c

199 anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab immu

200 pressure, driven by a corresponding shift in p FS.

201 effects, with no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

202 We found a significant interaction (p=0.051) between type of fractionation and treatment eff

203 vaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.001).

204 tern is more pronounced at higher latitudes (p = 0.023).

205 High-quality two-dimensional atomic layered p-n heterostructures are essential for high-performance

206 re severe spectrum with infantile lethality (p.Val112Glu).

207 ADMA reduced NOx and increased H2 O2 levels (p<0.001).

208 E2 plasma levels (p = .092) and time period of measurement (p = .975) did

209 n-6 fatty acid contents increased linearly (p<0.05) by raising the substitution levels of rice with

210 tionalized structural isomers of the type M2(p-dobdc) (p-dobdc(4-) = 2,5-dioxido-1,4-benzenedicarboxy

211 s (p = .092) and time period of measurement (p = .975) did not significantly affect corneal parameter

212 in fold changes of urinary PAH metabolites (p < 0.002).

213 % vs. 24.7 +/- 2.2% in vehicle-treated mice; p < 0.05) but not in the RA CMC group (24.1 +/- 1.2%).

214 t a pressure of 55 mmHg for 50 milliseconds (p < 0.05).

215 rial volumes (106 +/- 36 ml to 69 +/- 24 ml; p < 0.001).

216 d-diastolic (161 +/- 36 ml to 122 +/- 30 ml; p < 0.001) and left atrial volumes (106 +/- 36 ml to 69

217 11) and Mini-Mental State Examination (MMSE; p=0.004) at 1 year; these differences were not present a

218 lot analysis of pathway checkpoints, p-mTOR (p=0.03) and PI3K-alpha (P = 0.04) were downregulated in

219 area responses to loud sounds (multivariate p = .007) compared with trauma-exposed participants with

220 Individuals with common MYOC p.Gln368Ter variant were further analyzed separately to

221 er proportions of reward responsive neurons (p<0.01) and significantly lower proportions of loss resp

222 ower proportions of loss responsive neurons (p<0.05) in the STN, but not in the GPi.

223 on lipase inhibitory activity was observed (p<.0001).

224 O-caffeoylquinic acid (5-CQA), derivative of p-coumaroylquinic acid (HC2) and 3,5-dicaffeoylquinic ac

225 Homozygosity of p.Ser267Phe in SLC10A1 is associated with asymptomatic h

226 ore (95% CI: 0.01, 0.25) per log increase of p,p'-DDE).

227 ted to attenuation of the reflection loss of p-polarized light and multiple reflections within the wa

228 Percentage of p-STAT3(+) CD11c(+) cells was higher in Per a 10-adminis

229 which reveal a large and unexpected shift of p* with pressure, driven by a corresponding shift in p F

230 crystallization and phase transformation of p-xylene under high pressure.

231 , 7-11) and 54% in arm C (11%, 9-13; overall p<0.0001).

232 tivity in at-risk than control participants (p < .006).

233 ngenital myasthenic syndrome in one patient (p.Pro210Leu), to severe neurodevelopmental delay with br

234 (41%) than in CASPR2-IgG-positive patients (p = 0.033).

235 imed to determine the T-cell response to Phl p 12 in profilin-sensitized patients, by measuring the p

236 sk factors across ethnic/racial populations (p-trends < 0.01).

237 perature range (288.15-318.15)K at pressure, p=0.1MPa.

238 y [p = 0.003], and neuritic/glial-processes [p = 0.004]).

239 Arsenic is a promising p-type dopant; however, reproducible doping with high co

240 pGs in the gene proline rich 5 like (PRR5L) (p < 10(4)).

241 UROC] for wPRx was 0.73 versus 0.66 for PRx, p = 0.003).

242 bserved in the caudate (p = 0.1) or putamen (p = 0.8) following methylphenidate injection.

243 ding (all age ranges in caudate and putamen, p<0.0001) and (18)F-FDOPA uptake (in caudate: age </=50

244 anges, p<0.0001; in putamen: all age ranges, p<0.0001).

245 </=50 years, p=0.0002; all other age ranges, p<0.0001; in putamen: all age ranges, p<0.0001).

246 I 0.656-2.292; one-sided stratified log-rank p=0.77); at 24 months, the estimated probability of surv

247 nt difference between both groups (log rank, p 0.036).

248 inal-douche BD2 concentrations were reduced (p < 0.05) in women suffering rUTIs, compared to age-matc

249 btained as compared to the recently reported p-cresol sensor.

250 g to LGE presence and absence, respectively (p < 0.001).

251 control and hyperoxia groups, respectively (p = 0.077).

252 m(3) vs. 177.3 +/- 94.3 mm(3), respectively; p = 0.73).

253 HR=1.28 (95% CI: 1.07, 1.53), respectively; p-trend=0.002].

254 oth at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively;

255 and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006).

256 me (mean +/- SD) (87 +/- 41 vs 109 +/- 33 s; p = 0.037) and a longer delay before the start of chest

257 est compressions (109 +/- 77 vs 70 +/- 56 s; p = 0.038).

258 ty scores (Expanded Disability Status Scale [p = 0.009] and Instituto de Pesquisas de Cananeia [p = 0

259 nd improved renal function in CKD-RDN sheep (p < 0.0001 for 2 and 5 months vs. pre-RDN).

260 ard ratio 0.62 [95% CI 0.47-0.80]; one-sided p<0.001).

261 lacebo group (HR 0.76 [0.60-0.97], one-sided p=0.014).

262 ISTRY gave a genome-wide significant signal (p=1.12 x 10(-10)) on chromosome 5 spanning three genes:

263 association was only marginally significant (p = 0.054).

264 litudes and PPGDC levels showed significant (p < 0.001) changes during the increase in shear rates an

265 ted in 2006, about 29.5% showed significant (p < 0.05) increasing trends of MODIS NDVI after implemen

266 necrotic/apoptotic injury and significantly (p < 0.05) improved function and recipient Lewis rat surv

267 degrees C) storage exhibited significantly (p < 0.05) decreased acute necrotic/apoptotic injury and

268 Moreover, significantly (p<0.01) higher omega3 PUFAs % recovery and lower peroxid

269 es to date using a score of 62 RA risk SNPs (p < 5 * 10(-8)) as instrumental variable (IV).

270 Cellular imaging using a phospho-specific p-T153/Y155 antibody showed that phosphorylated TDP-43 w

271 -/-) macrophages following TLR2 stimulation (p < 0.01).

272 atients during SWS and 461 (61%) during STM (p<0.0001).

273 F had significantly higher tensile strength (p = 0.00).

274 ons were stronger in North American studies (p = 0.010) and those measuring hs-cTnT rather than hs-cT

275 the genes that were identified in our study (p = 1.54 x 10(-17)).

276 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.3

277 l parameters in pressed honey were superior (p<0.05).

278 tual performance in self-management support (p<0.001).

279 heterozygous mutant PEX6 allele (c.2578C>T [p.Arg860Trp]) was overrepresented due to allelic express

280 eing observed for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and also microbiota-derived AhR ligands

281 receptor (AHR) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) prevents the proper formation of craniof

282 y recruited to the nucleoli, suggesting that p-T153/Y155 regulates a previously unappreciated functio

283 The p.H67R variant reduced nuclear entry of p50 and showed d

284 sed with drug concentration and exceeded the p-glycoprotein efflux when the latter was saturated.

285 We show that the p.Arg90His substitution, which is reported to cause redu

286 ribed which are conjugatively linked through p-ter-phenyl (PPP), ter-thiophene (TTT) and alternating

287 ions, with sensitivity decreasing over time (p=0.04).

288 ning by training type corrected, p = 0.01 to p = 0.05) 1 month later.

289 ed positive associations between exposure to p,p'-DDE and BMI z-score (beta=0.13 BMI z-score (95% CI:

290 of 176.7 +/- 152.4 s of arc after training (p < 0.01).

291 And by combining a transparent p-AlGaN contact layer, an electron blocking layer and us

292 control versus 95.72 x 106/l +/- 8.0 trauma, p < 0.05) and reduced leukocyte cytokine secretion in re

293 control versus 1,092 x 106/l +/- 165 trauma, p < 0.0005) and CD14+HLA-DRlow/- monocytes (34.96 x 106/

294 5% vs 50.0% with standard medical treatment; p = 0.004), especially in patients with multiple organ f

295 The siblings also had the pathogenic variant p.Ala13Thr variant in MYL2, a known gene for HCM.

296 eneralized equation can be expressed as Wh = p(ln h)(q), where h is hmax/h, hmax being the peak ampli

297 11, a marker of recycling endosomes, whereas p-ERK associates predominantly with a distinct KSR1-posi

298 f cytochrome c by replacing tyrosine 48 with p-carboxy-methyl-l-phenylalanine (pCMF).

299 s with a mean (+/-SD) of 28.0+/-5.079 years (p=0.746).

300 F-FDOPA uptake (in caudate: age </=50 years, p=0.0002; all other age ranges, p<0.0001; in putamen: al

301 lume hospital were younger (64.7 vs 72.7 yr; p < 0.001) and were more likely to have commercial insur